Fusion Antibodies (LSE:FAB) Current Deferred Revenue: £0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:FAB Fusion Antibodies PLC LSE:FAB
26 GF Score
Price £0.11
GF Value £0.04
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Fusion Antibodies Current Deferred Revenue?

Fusion Antibodies LSE:FAB -2.33% 26 Current Deferred Revenue is £0.00 Mil as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 26/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Fusion Antibodies's current deferred revenue for the quarter that ended in Sep. 2025 was £0.00 Mil.

Fusion Antibodies Current Deferred Revenue Related Terms

Fusion Antibodies Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Fusion Antibodies's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies Current Deferred Revenue Chart

Fusion Antibodies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:FAB
26GF Score
Fusion Antibodies PLC LSE:FAB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of £0.00 Mil mean?
Fusion Antibodies (LSE:FAB) has a Current Deferred Revenue of £0.00 Mil as of Sep. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Fusion Antibodies and its competitors.
Is Fusion Antibodies' Current Deferred Revenue too high?
Fusion Antibodies' current Current Deferred Revenue is £0.00 Mil. Overall, Fusion Antibodies has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Current Deferred Revenue compare to VRTX and REGN?
Fusion Antibodies' Current Deferred Revenue of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current Current Deferred Revenue is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 162.5% above its estimated fair value. The current Current Deferred Revenue is £0.00 Mil. Fusion Antibodies' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Current Deferred Revenue is £0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?

Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued. The current stock price of £0.11 is trading 162.5% above its estimated GF Value™ of £0.04. GuruFocus considers Fusion Antibodies to be Significantly Overvalued.

Key valuation signals for LSE:FAB:

  • Current Deferred Revenue: £0.00 Mil
  • GF Value™: £0.04 vs. price of £0.11 (162.5% above fair value)
  • GF Score™: 26/100 with 4 warning signs

No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
26GF Score

Get the complete analysis for LSE:FAB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.11
Price
£0.04
GF Value